Vertex and CRISPR Therapeutics to develop gene-editing treatment

14-12-2017

Vertex and CRISPR Therapeutics to develop gene-editing treatment

ralwel / iStockphoto.com

US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.


Vertex Pharmaceuticals, CRISPR, CRISPR Therapeutics, commercialisation, licence, gene editing, CRISPR/Cas9

LSIPR